Introduction
============

Pancreatic cancer is one of the top five causes of cancer-associated mortality with a fatality rate of 95%; the majority of patients with pancreatic cancer have a delayed diagnosis, as early diagnosis is difficult ([@b1-ol-0-0-10624]). Recent data showed that pancreatic cancer has the lowest 5-year relative survival rate (9%) among all cancer types ([@b2-ol-0-0-10624]). Pancreatic ductal adenocarcinoma (PDAC) accounts for a majority of pancreatic cancer cases and is an aggressive and difficult malignancy to treat ([@b3-ol-0-0-10624]). Despite advancing knowledge of the mechanisms of carcinogenicity and improvement in diagnosis and management, the prognosis remains poor for patients with PDAC ([@b3-ol-0-0-10624]). Therefore, new mechanisms and biomarkers are needed to improve the prognosis and detection of PDAC in patients.

MicroRNAs (miRNAs) are a class of small non-coding RNAs (ncRNAs), 18--25 nucleotides long, that negatively control gene expression at the mRNA and protein level ([@b4-ol-0-0-10624]). Accumulating evidence has suggested that miRNAs are dysregulated in various types of cancers, including PDAC ([@b5-ol-0-0-10624]). As the absence of symptoms in early disease results in a late diagnosis of PDAC, numerous miRNAs, such as miR-21, miR-155, miR-196 and miR-210, have been identified as biomarkers for PDAC ([@b5-ol-0-0-10624]). Understanding the mechanisms contributing to miRNA dysregulation may help to improve PDAC diagnosis and treatment.

Another class of ncRNAs are circular RNAs (circRNAs), which function as miRNA sponges, thus serving as competitive inhibitors and suppressing the ability of the miRNA to bind its mRNA targets ([@b6-ol-0-0-10624],[@b7-ol-0-0-10624]). Although circRNAs were discovered in RNA viruses in the 1970s, these molecules were considered as molecular flukes or products of aberrant RNA splicing ([@b7-ol-0-0-10624]). Recent evidence indicates that circRNAs may serve important roles in cancers, including bladder cancer ([@b8-ol-0-0-10624]), esophageal squamous cell carcinoma ([@b9-ol-0-0-10624]), breast cancer ([@b10-ol-0-0-10624]), basal cell carcinoma ([@b11-ol-0-0-10624]), cutaneous squamous cell carcinoma ([@b12-ol-0-0-10624]), colorectal cancer ([@b13-ol-0-0-10624]) and PDAC ([@b14-ol-0-0-10624]). In the present study, microarray data downloaded from Gene Expression Omnibus (GEO) were used to explore the roles of circRNAs and miRNAs in PDAC and to provide novel insights into PDAC biology.

Materials and methods
=====================

### Microarray data

Raw gene expression profile datasets GSE69362, GSE79634 and GSE43796 were downloaded from the GEO database (<http://www.ncbi.nlm.nih.gov/geo>). The datasets GSE69362 and GSE79634 were analyzed on the GPL19978 Agilent-069978 Arraystar Human CircRNA microarray V1 platform, which analyzes 5,396 human circRNAs at the same time. The dataset GSE43796 was analyzed on the GPL15159 Agilent-031181 Unrestricted Human miRNA V16.0 Microarray platform, which can detect 1,205 mature human miRNAs.

The GSE69362 dataset accessed the expression of circRNAs in six pairs of PDAC and adjacent normal tissues. The GSE79634 dataset accessed the expression of circRNAs in 20 pairs of samples. GSE43796 detected the expression of miRNAs in solid-pseudopapillary neoplasm of pancreas (n=14), ductal adenocarcinoma (n=6), neuroendocrine tumor (n=6) and non-neoplastic pancreas (n=5). The six PDAC tissues and the five non-neoplastic pancreases from GSE43796 were included in the present study.

### Data analysis

Differentially expressed genes were identified using the limma package in the R software (version 3.3.2; <http://www.r-project.org>) ([@b15-ol-0-0-10624]). Raw data was read and background was corrected and normalized. Probes that were ≥10% brighter compared with the negative controls on at least one-half of arrays were averaged for each gene. The array weights were estimated and used in the linear model analysis. Paired or unpaired Student\'s t-test was used to identify differentially expressed genes between tumor tissues and normal tissues. The Benjamini-Hochberg method was used to correct for multiple comparisons ([@b16-ol-0-0-10624]). Differentially expressed genes between tumor tissues and normal tissues were identified, using fold-change \>2 and adjusted P\<0.05 as selection criteria.

### miRNA prediction

As certain sequences of circRNAs in circBase may differ from the mature sequence of circRNAs ([@b17-ol-0-0-10624]), sequences of the circRNAs were extracted using circPrimer (version 1.2; <http://www.bioinf.com.cn>) ([@b18-ol-0-0-10624]), which was developed by our laboratory. As exon-derived circRNAs have been demonstrated to serve as miRNA sponges, the 256 differentially expressed circRNAs were annotated using circPrimer and only 214 exon-derived circRNAs were used for further analysis.

The sequences of the 214 circRNAs and 20 differentially expressed miRNAs were saved as FASTA format. circRNA/miRNA interactions were predicted using circMir (version 1.0; <http://www.bioinf.com.cn>), which used the miRanda ([@b19-ol-0-0-10624]) and RNAhybrid ([@b20-ol-0-0-10624]) algorithms to predict miRNAs that bind to spliced junctions of circRNAs. As the prediction algorithm often suffers from high false positive rates, only the circRNA/miRNA interactions predicted by the two independent algorithms were used. Cytoscape software version 3.1.1 (<http://cytoscape.org>) was utilized to construct a possible functional network of the differentially expressed circRNAs and miRNAs.

### Pathway analysis of circRNA gene symbols

circRNA host genes were submitted to the web-based tool DAVID (<http://david.abcc.ncifcrf.gov>) to perform a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The following default thresholds were used: Count=2 and EASE (a modified Fisher\'s Exact test P-value)=0.1. The enriched pathways and gene symbols were imported into Cytoscape software version 3.1.1 to construct a network.

Results
=======

### Overview of the datasets

The distribution of normalized signal intensities of the datasets indicated that microarray quality for circRNA and miRNA was good ([Fig. 1A and B](#f1-ol-0-0-10624){ref-type="fig"}, respectively). The expression levels of the majority of genes were correlated between PDAC and normal tissues, although there were a number of differentially expressed circRNAs and miRNAs ([Fig. 1C and D](#f1-ol-0-0-10624){ref-type="fig"}, respectively). Volcano plots were generated to visualize the relationship of fold-change and statistical significance for circRNAs and miRNAs ([Fig. 1E and F](#f1-ol-0-0-10624){ref-type="fig"}, respectively).

### Identification of differentially expressed genes

Compared with adjacent normal tissues, there were 256 differentially expressed circRNAs in PDAC tissues, including 115 upregulated circRNAs and 141 downregulated circRNAs. The top 40 differentially expressed circRNAs in PDAC are presented in [Table I](#tI-ol-0-0-10624){ref-type="table"}, and the full list is presented in [Table SI](#SD1-ol-0-0-10624){ref-type="supplementary-material"}. Eight upregulated miRNAs and 12 downregulated miRNAs were identified in PDAC ([Table II](#tII-ol-0-0-10624){ref-type="table"}).

### Prediction of circRNA/miRNA interaction

circRNAs may upregulate the expression of target genes of miRNAs by sequestering the miRNAs. In the present study, a total of 51 circRNA/miRNA interactions were identified and a possible functional network of the differentially expressed circRNAs and miRNAs was generated ([Fig. 2](#f2-ol-0-0-10624){ref-type="fig"}). The detailed results including miRNA binding sites are presented in [Table SII](#SD1-ol-0-0-10624){ref-type="supplementary-material"}.

### KEGG pathway analysis

Previous studies have shown that circRNAs modulate the expression of their host genes ([@b6-ol-0-0-10624],[@b7-ol-0-0-10624]). Thus, KEGG pathway enrichment analysis was performed using host genes of differentially expressed circRNAs. A total of 41 host genes were enriched in 17 pathways ([Fig. 3](#f3-ol-0-0-10624){ref-type="fig"}; [Table SIII](#SD1-ol-0-0-10624){ref-type="supplementary-material"}). B-Raf proto-oncogene, serine/threonine kinase (BRAF) and mitogen-activated protein kinase kinase 2 (MAP2K2) interacted with the highest number of pathways, which suggested that these two genes may serve important roles in PDAC.

Since apoptosis and proliferation are associated with cancer development and progression, the subnetworks of these pathways were extracted from the 17 enriched KEGG pathways. Subsequently, a new network was constructed with these extracted subnetworks, which included 16 host genes that potentially affect cell survival directly or indirectly ([Fig. 4](#f4-ol-0-0-10624){ref-type="fig"}). Thus, target circRNAs were obtained for future studies.

Discussion
==========

Two former studies from one research group have profiled the expression of circRNAs in PDAC ([@b14-ol-0-0-10624],[@b21-ol-0-0-10624]). However, only six pairs of PDAC and adjacent normal tissues were profiled and the sample size was relatively small. In the present study, comprehensive analysis with 26 samples from GEO was performed to explore the putative roles of circRNAs in PDAC and to provide novel insights into PDAC biology. The regulatory roles of circRNAs in cancer are attracting increasing attention. Li *et al* ([@b14-ol-0-0-10624]) have identified a number of dysregulated circRNAs in PDAC. Another study further investigated the expression level of one dysregulated circRNA termed circ-LDLRAD3, which was upregulated in pancreatic cancer cell lines as well as tumors and plasma from patients with pancreatic cancer, and circ-LDLRAD3 was demonstrated to be associated with invasion and metastasis of pancreatic cancer ([@b22-ol-0-0-10624]). circRNA exerts its regulatory roles through sequestering cancer-related miRNAs ([@b13-ol-0-0-10624],[@b23-ol-0-0-10624]--[@b26-ol-0-0-10624]). Therefore, differentially expressed circRNAs and miRNAs in PDAC were used to predict circRNA/miRNA interactions. circRNAs may upregulate the expression of target genes of miRNAs by sequestering the miRNAs. In addition, if circRNAs and their host genes share the same miRNA binding sites, the circRNAs may upregulate the expression of their host genes. In the present study, a total of 51 circRNA/miRNA interactions were identified using 256 differentially expressed circRNAs and 20 differentially expressed miRNAs and a network of the circRNA/miRNA interactions was produced to illustrate the relationships of these genes. The network contained 41 circRNA nodes, 14 miRNA nodes and 51 edges. The number of connections indicates gene involvement in various pathways in PDAC; therefore, the nodes connecting multiple genes may be worth further investigation using experimental methods.

circRNAs are encoded in exons and/or introns of their parental genes ([@b27-ol-0-0-10624]). Previous studies have shown that circRNAs modulate the expression of their parental genes ([@b6-ol-0-0-10624],[@b7-ol-0-0-10624],[@b28-ol-0-0-10624],[@b29-ol-0-0-10624]). To explore the potential roles of circRNAs, the predominant pathways of the gene symbols of the differentially expressed circRNAs were identified by a pathway-mapping tool. BRAF and MAP2K2 interacted with the highest number of pathways. BRAF and MAP2K2 are two important members of MAPK signaling pathway, which is associated with PDAC ([@b30-ol-0-0-10624],[@b31-ol-0-0-10624]). The results of the present study indicated that the majority of the inspected genes achieved their effects through the PI3K/AKT signaling pathway. Pancreatic acinar-to-ductal metaplasia is an initiating event that is induced through the PI3K/AKT signaling pathway and can progress to PDAC ([@b32-ol-0-0-10624]). Another pathway involving cell proliferation is the Wnt/β-catenin signaling pathway. Sox15 exerts its tumor-suppressive effects in pancreatic cancer by suppressing the Wnt/β-catenin signaling pathway ([@b33-ol-0-0-10624]). Recent data has suggested that the WNT/β-catenin signaling pathway upregulated the expression of cellular communication network factor 1 and consequently enhanced pancreatic cancer development and malignancy ([@b34-ol-0-0-10624]). In the present study, the aim was to identify circRNA-associated pathways that are involved in the development of PDAC.

As well as acting as miRNA sponges, circRNAs may exert their function through protein binding ([@b35-ol-0-0-10624]), protein coding ([@b36-ol-0-0-10624],[@b37-ol-0-0-10624]), modulating transcriptional activity of RNA polymerase II ([@b38-ol-0-0-10624]) and competing with linear splicing ([@b39-ol-0-0-10624]). Cellular localization has been linked with physiological function and functional mechanism of circRNAs ([@b40-ol-0-0-10624],[@b41-ol-0-0-10624]). Most circRNAs comprise of exonic sequences and are located in the cytoplasm, whereas a small number of intron-derived circRNAs are located in the nucleus ([@b42-ol-0-0-10624]). Therefore, it is necessary to confirm the cellular localization of a circRNA before studying its roles.

The potential limitations of the present study need to be considered when interpreting the results. Firstly, the results were not verified in clinical samples; differentially expressed circRNAs and miRNAs may be verified using reverse transcription-quantitative PCR in larger clinical samples. Secondly, the circRNA/miRNA interactions were predicted using a bioinformatics method and should be confirmed by the luciferase reporter assay. Thirdly, host gene symbols of circRNAs were used to carry out the KEGG pathway enrichment analysis; whether these circRNAs exert an effect in the enriched pathways should be confirmed using experimental methods.

In conclusion, the potential roles of circRNAs in PDAC were explored using bioinformatics. In total, 256 differentially expressed circRNAs and 20 differentially expressed miRNAs were identified in PDAC tissues compared with normal tissues. The roles of circRNAs in PDAC were explored by prediction of circRNA/miRNA interactions and KEGG pathway enrichment analysis. The circRNA-associated pathways presented in present study could help uncover the effect of circRNAs on PDAC development. Further study confirming the effects of these circRNAs on PDAC development are required in order to improve PDAC diagnosis and therapy.
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![Overview of the microarray datasets. (A) Box plots of the distributions of normalized signal intensities of the circRNA datasets. (B) Box plots for the distributions of normalized signal intensities of the miRNA datasets. (C) Scatter plots of the circRNA microarray signal values of between PDAC and adjacent normal tissues. Red dots represent upregulated circRNAs compared with normal tissues; green dots represent downregulated circRNAs compared with normal tissues; black dots represent equally expressed circRNAs. (D) Scatter plots of the miRNA microarray signal values between PDAC and normal tissues. Red dots represent upregulated miRNAs compared with normal tissues; green dots represent downregulated miRNAs compared with normal tissues; black dots represent equally expressed miRNAs. (E) Volcano plot of circRNA datasets. Red dots represent differentially expressed circRNAs. (F) Volcano plot of miRNA datasets. Red dots represent differentially expressed miRNAs. circRNA, circular RNA; miRNA, microRNA; PDAC, pancreatic ductal adenocarcinoma.](ol-18-03-2923-g00){#f1-ol-0-0-10624}

![Networks of circRNA/miRNA interactions predicted using miRanda and RNAhybrid software. Red circles represent upregulated circRNAs; green circles represent downregulated circRNAs; pink squares represent upregulated miRNAs; light green squares represent downregulated miRNAs. The size of the circles and squares represents the fold-change of the genes. circRNA, circular RNA; miRNA, microRNA.](ol-18-03-2923-g01){#f2-ol-0-0-10624}

![Network of KEGG pathways and circRNA host gene symbols. Red circles represent upregulated circRNA host genes; green circles represent downregulated circRNA host genes; the size of the circles represents the fold-change of the circRNAs. As both hsa_circ_0000676 and hsa_circ_0000679 are derived from ABCC1, they are indicated as ABCC1^\#^ and ABCC1\*, respectively. circRNA, circular RNA; KEGG, Kyoto Encyclopedia of Genes and Genomes.](ol-18-03-2923-g02){#f3-ol-0-0-10624}

![Pathways associated with apoptosis or proliferation. Orange ellipses represent the host gene symbols for differentially expressed circRNAs and gray ellipses represent the downstream genes regulated by parental genes of the circRNAs in the KEGG pathways; green solid lines represent a direct activation effect; green dotted lines represent an indirect activation effect; red solid lines represent a direct inhibition effect; red dotted lines represent an indirect inhibition effect. circRNA, circular RNA; KEGG, Kyoto Encyclopedia of Genes and Genomes; +p, phosphorylation; -p, dephosphorylation.](ol-18-03-2923-g03){#f4-ol-0-0-10624}

###### 

Top 40 differentially expressed circRNAs in pancreatic ductal adenocarcinoma.

  A, Upregulated circRNAs                                                           
  ------------------------------- --------------- ----------------- --------------- --------------------------------------------------------------------
  hsa_circ_0000977                NOL10           27.155            1.498×10^−7^    2.223×10^−6^
  hsa_circ_0006220                TADA2A          24.448            3.806×10^−8^    8.269×10^−7^
  hsa_circ_0001666                FAM120B         17.041            5.381×10^−8^    1.096×10^−6^
  hsa_circ_0043278                TADA2A          16.234            5.970×10^−8^    1.110×10^−6^
  hsa_circ_0078297                MTHFD1L         6.870             9.875×10^−6^    5.566×10^−5^
  hsa_circ_0013912                POLR3C          6.834             2.484×10^−5^    1.198×10^−4^
  hsa_circ_0003600                SOX13           5.984             8.372×10^−7^    8.265×10^−6^
  hsa_circ_0044436                KAT7            5.272             4.677×10^−6^    3.019×10^−5^
  hsa_circ_0018909                VDAC2           5.108             3.209×10^−5^    1.463×10^−4^
  hsa_circ_0029634                ZMYM2           4.829             2.919×10^−7^    3.679×10^−6^
  hsa_circ_0001907                LOC100507412    4.182             1.461×10^−9^    6.333×10^−8^
  hsa_circ_0066147                SFMBT1          4.079             2.067×10^−12^   1.165×10^−9^
  hsa_circ_0092314                RANBP1          3.967             2.826×10^−5^    1.317×10^−4^
  hsa_circ_0050102                PGPEP1          3.741             6.531×10^−7^    6.735×10^−6^
  hsa_circ_0006117                PTPRA           3.722             1.245×10^−12^   1.053×10^−9^
  hsa_circ_0000912                FCHO1           3.613             1.603×10^−6^    1.327×10^−5^
  hsa_circ_0080210                GRB10           3.607             5.627×10^−5^    2.310×10^−4^
  hsa_circ_0030292                FAM124A         3.515             3.366×10^−10^   2.159×10^−8^
  hsa_circ_0082452                EXOC4           3.503             1.274×10^−10^   1.134×10^−8^
  hsa_circ_0005105                SEC24A          3.484             3.878×10^−7^    4.401×10^−6^
                                                                                    
  **B, Downregulated circRNAs**                                                     
                                                                                    
  **circRNA**                     **Host gene**   **Fold change**   **P-value**     **Adjusted P-value^[a](#tfn1-ol-0-0-10624){ref-type="table-fn"}^**
                                                                                    
  hsa_circ_0000518                RPPH1           6.986             2.148×10^−6^    1.649×10^−5^
  hsa_circ_0005556                NBAS            5.853             9.288×10^−7^    8.823×10^−6^
  hsa_circ_0005918                FCHSD2          5.249             5.710×10^−6^    3.537×10^−5^
  hsa_circ_0081188                SLC25A13        5.129             3.563×10^−7^    4.156×10^−6^
  hsa_circ_0013587                LRIG2           4.969             1.231×10^−8^    3.304×10^−7^
  hsa_circ_0006110                USP34           4.813             1.952×10^−6^    1.536×10^−5^
  hsa_circ_0005273                PTK2            4.716             5.497×10^−6^    3.455×10^−5^
  hsa_circ_0003930                GGNBP2          4.478             1.848×10^−6^    1.474×10^−5^
  hsa_circ_0000511                RPPH1           4.398             9.923×10^−7^    9.271×10^−6^
  hsa_circ_0000517                RPPH1           4.193             1.349×10^−5^    7.288×10^−5^
  hsa_circ_0005394                ZC3H7A          4.102             6.545×10^−5^    2.594×10^−4^
  hsa_circ_0092367                SNORD116-14     4.099             3.443×10^−4^    1.036×10^−3^
  hsa_circ_0000520                RPPH1           3.981             3.628×10^−4^    1.082×10^−3^
  hsa_circ_0003831                PPP2R5C         3.950             1.410×10^−6^    1.210×10^−5^
  hsa_circ_0006944                GTF2I           3.746             5.175×10^−5^    2.172×10^−4^
  hsa_circ_0061749                BRWD1           3.745             1.933×10^−5^    9.955×10^−5^
  hsa_circ_0000958                PPP1R12C        3.704             3.575×10^−5^    1.603×10^−4^
  hsa_circ_0000662                AXIN1           3.700             2.699×10^−4^    8.420×10^−4^
  hsa_circ_0079385                ZDHHC4          3.605             9.123×10^−4^    2.374×10^−3^
  hsa_circ_0001288                SETD2           3.600             6.598×10^−6^    4.043×10^−5^

The P-value was adjusted using the Benjamini-Hochberg method. circRNA; circular RNA.

###### 

Differentially expressed miRNAs in pancreatic ductal adenocarcinoma.

  A, Upregulated miRNAs                                          
  ----------------------------- ----------------- -------------- --------------------------------------------------------------------
  hsa-miR-210-3p                13.480            2.649×10^−6^   4.584×10^−4^
  hsa-miR-135b-5p               11.830            2.289×10^−6^   4.584×10^−4^
  hsa-miR-203a-3p               6.798             3.989×10^−5^   3.450×10^−3^
  hsa-miR-222-3p                4.139             1.787×10^−4^   8.834×10^−3^
  hsa-miR-196b-5p               3.216             1.923×10^−3^   3.379×10^−2^
  hsa-miR-200a-5p               3.080             5.337×10^−4^   1.467×10^−2^
  hsa-miR-221-3p                3.003             1.204×10^−3^   2.777×10^−2^
  hsa-miR-181b-5p               2.791             1.953×10^−3^   3.379×10^−2^
                                                                 
  **B, Downregulated miRNAs**                                    
                                                                 
  **miRNA**                     **Fold change**   **P-value**    **Adjusted P-value^[a](#tfn2-ol-0-0-10624){ref-type="table-fn"}^**
                                                                 
  hsa-miR-148a-3p               9.347             1.815×10^−3^   3.379×10^−2^
  hsa-miR-144-3p                7.768             2.443×10^−5^   2.818×10^−3^
  hsa-miR-451a                  7.255             1.090×10^−4^   6.285×10^−3^
  hsa-miR-376c-3p               3.198             1.902×10^−3^   3.379×10^−2^
  hsa-miR-204-5p                2.916             4.908×10^−4^   1.467×10^−2^
  hsa-miR-154-5p                2.897             2.396×10^−4^   1.036×10^−2^
  hsa-miR-381-3p                2.665             2.865×10^−3^   4.425×10^−2^
  hsa-miR-654-3p                2.382             5.511×10^−4^   1.467×10^−2^
  hsa-miR-377-3p                2.365             2.942×10^−3^   4.425×10^−2^
  hsa-miR-136-3p                2.359             9.045×10^−4^   2.235×10^−2^
  hsa-miR-557                   2.275             3.002×10^−4^   1.154×10^−2^
  hsa-miR-487b-3p               2.271             3.903×10^−4^   1.350×10^−2^

The P-value was adjusted using the Benjamini-Hochberg method. circRNA; circular RNA.
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